HK35196A - Method of reducing immunoglobulin e responses - Google Patents

Method of reducing immunoglobulin e responses Download PDF

Info

Publication number
HK35196A
HK35196A HK35196A HK35196A HK35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A
Authority
HK
Hong Kong
Prior art keywords
human
monoclonal antibody
immunoglobulin
antagonist
human interleukin
Prior art date
Application number
HK35196A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert L Coffman
Egbert De Vries Jan
Original Assignee
Schering Biotech Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK35196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Biotech Corporation filed Critical Schering Biotech Corporation
Publication of HK35196A publication Critical patent/HK35196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK35196A 1988-02-02 1996-02-29 Method of reducing immunoglobulin e responses HK35196A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15141388A 1988-02-02 1988-02-02

Publications (1)

Publication Number Publication Date
HK35196A true HK35196A (en) 1996-03-08

Family

ID=22538655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK35196A HK35196A (en) 1988-02-02 1996-02-29 Method of reducing immunoglobulin e responses

Country Status (20)

Country Link
US (1) US5676940A (da)
EP (2) EP0327283B1 (da)
JP (1) JPH03500050A (da)
KR (1) KR900700132A (da)
AT (1) ATE93144T1 (da)
AU (1) AU629536B2 (da)
CA (1) CA1341477C (da)
DE (1) DE68908431T2 (da)
DK (1) DK183590A (da)
ES (1) ES2058490T3 (da)
FI (1) FI903827A0 (da)
HK (1) HK35196A (da)
HU (1) HU211059B (da)
IE (1) IE63097B1 (da)
IL (1) IL89124A (da)
MY (1) MY107079A (da)
NZ (1) NZ227812A (da)
PT (1) PT89573B (da)
WO (1) WO1989006975A1 (da)
ZA (1) ZA89766B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU648777B2 (en) * 1989-12-04 1994-05-05 Schering Corporation Method of treating septic shock
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
US5252677A (en) * 1990-11-20 1993-10-12 Mitsubishi Petrochemical Company Limited Functionalized olefin polymers
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
ES2291455T3 (es) 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
DE122006000007I2 (de) * 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.

Also Published As

Publication number Publication date
FI903827A7 (fi) 1990-08-01
MY107079A (en) 1995-09-30
EP0327283B1 (en) 1993-08-18
HUT54214A (en) 1991-01-28
KR900700132A (ko) 1990-08-11
AU3038389A (en) 1989-08-25
DE68908431T2 (de) 1993-12-23
ZA89766B (en) 1989-09-27
US5676940A (en) 1997-10-14
JPH03500050A (ja) 1991-01-10
IE890302L (en) 1989-08-02
DK183590A (da) 1990-09-27
PT89573B (pt) 1994-01-31
HU891044D0 (en) 1990-11-28
EP0397764A1 (en) 1990-11-22
WO1989006975A1 (en) 1989-08-10
FI903827A0 (fi) 1990-08-01
EP0327283A1 (en) 1989-08-09
AU629536B2 (en) 1992-10-08
ATE93144T1 (de) 1993-09-15
IL89124A0 (en) 1989-08-15
PT89573A (pt) 1989-10-04
IL89124A (en) 1994-10-21
NZ227812A (en) 1991-09-25
CA1341477C (en) 2005-03-29
HU211059B (en) 1995-10-30
IE63097B1 (en) 1995-03-22
ES2058490T3 (es) 1994-11-01
DK183590D0 (da) 1990-08-01
DE68908431D1 (de) 1993-09-23

Similar Documents

Publication Publication Date Title
EP0327283B1 (en) Method of reducing immunoglobulin e responses
EP1003781B1 (en) Interleukin-18 binding proteins, their preparation and use
KR100483494B1 (ko) 감마 인터페론에 대한 인간화 항체
US5096704A (en) Method of treating eosinophilia
US20160024220A1 (en) Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
CA2002144C (en) Method of preventing or reducing eosinophilia
EP0504307B1 (en) Method of treating septic shock
US7704944B2 (en) Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
AU650013B2 (en) BCRF1 antagonists for treating Epstein-Barr virus infections

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050130